{"corpus_id":22887630,"paper_sha":"2bbd8b1c0d7bd429ead534e9a57c0879b27716d7","doi":"10.1182/BLOOD-2004-08-3175","arxiv_id":null,"pmid":15494430,"pmcid":null,"mag_id":2169578616,"dblp_id":null,"acl_id":null,"title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.","year":2005,"publication_date":"2005-02-15","venue":"Blood","journal":{"name":"Blood","pages":"\n          1417-23\n        ","volume":"105 4"},"journal_issn":null,"journal_title":null,"publication_types":["Study","JournalArticle","ClinicalTrial"],"pubmed_pub_types":["Clinical Trial","Comparative Study","Journal Article","Multicenter Study","Randomized Controlled Trial","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine"],"reference_count":45,"citation_count":996,"influential_citation_count":36,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Adult","mj":false,"ui":"D000328"},{"d":"Antibodies, Monoclonal","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"adverse effects","mj":false,"ui":"Q000009"}],"ui":"D000911"},{"d":"Antibodies, Monoclonal, Murine-Derived","mj":false,"ui":"D058846"},{"d":"Antineoplastic Combined Chemotherapy Protocols","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D000971"},{"d":"Cyclophosphamide","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"adverse effects","mj":false,"ui":"Q000009"}],"ui":"D003520"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Follow-Up Studies","mj":false,"ui":"D005500"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Lymphoma, Follicular","mj":false,"qs":[{"q":"drug therapy","mj":true,"ui":"Q000188"}],"ui":"D008224"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"Prednisone","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"adverse effects","mj":false,"ui":"Q000009"}],"ui":"D011241"},{"d":"Prospective Studies","mj":false,"ui":"D011446"},{"d":"Rituximab","mj":false,"ui":"D000069283"},{"d":"Vincristine","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"adverse effects","mj":false,"ui":"Q000009"}],"ui":"D014750"}],"chemicals":[{"n":"Antibodies, Monoclonal","ui":"D000911","reg":"0"},{"n":"Antibodies, Monoclonal, Murine-Derived","ui":"D058846","reg":"0"},{"n":"Rituximab","ui":"D000069283","reg":"4F4X42SYQ6"},{"n":"Vincristine","ui":"D014750","reg":"5J49Q6B70F"},{"n":"Cyclophosphamide","ui":"D003520","reg":"8N3DW7272P"},{"n":"Prednisone","ui":"D011241","reg":"VB0R961HZT"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://ashpublications.org/blood/article-pdf/105/4/1417/1706471/zh800405001417.pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/2bbd8b1c0d7bd429ead534e9a57c0879b27716d7","s2_open_access_license":null,"s2_open_access_status":"BRONZE","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"The combination of cyclophosphamide, vincristine, and prednisone (CVP) is one of several standard treatment options for advanced follicular lymphoma. This, like similar chemotherapeutic regimens, induces response rates of 60% to 80%, with a median response duration of under 2 years. Rituximab, a chimeric monoclonal antibody against CD20, is active in follicular lymphoma, both as monotherapy and in combination with chemotherapy. Previously untreated patients with stages III to IV follicular lymphoma were randomly assigned to receive either 8 cycles of CVP plus rituximab (R-CVP; n = 162) or CVP (n = 159). Overall and complete response rates were 81% and 41% in the R-CVP arm versus 57% and 10% in the CVP arm, respectively (P < .0001). At a median follow-up of 30 months, patients treated with R-CVP had a very significantly prolonged time to progression (median 32 months versus 15 months for CVP; P < .0001). Median time to treatment failure was 27 months in patients receiving R-CVP and 7 months in the CVP arm (P < .0001). Rituximab did not add significantly to the toxicity of CVP. The addition of rituximab to the CVP regimen significantly improves the clinical outcome in patients with previously untreated advanced follicular lymphoma, without increased toxicity.","claims":[{"public_id":"cl_698df5dac3c0637f5a37579888152525","status":"active","text":"Adding rituximab to CVP significantly improves clinical outcome in previously untreated advanced follicular lymphoma without increasing toxicity.","confidence":0.9,"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_698df5dac3c0637f5a37579888152525"},{"public_id":"cl_45e5c8aa8425d47e889c8090ceb32ed9","status":"active","text":"Median time to treatment failure was 27 months for R-CVP versus 7 months for CVP (P < .0001).","confidence":0.95,"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_45e5c8aa8425d47e889c8090ceb32ed9"},{"public_id":"cl_d9b6d4b03d4f2ee6106c5cf2608477db","status":"active","text":"Previously untreated patients with stage III to IV follicular lymphoma were randomly assigned to receive either R-CVP (n = 162) or CVP alone (n = 159).","confidence":0.95,"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_d9b6d4b03d4f2ee6106c5cf2608477db"},{"public_id":"cl_d73df164fef5b4ddee2c15a85eceb841","status":"active","text":"R-CVP achieved higher overall and complete response rates than CVP alone (81% and 41% versus 57% and 10%, respectively; P < .0001).","confidence":0.95,"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_d73df164fef5b4ddee2c15a85eceb841"},{"public_id":"cl_4bd9e4c4d47baf8c957322913974bf77","status":"active","text":"R-CVP significantly prolonged time to progression compared with CVP (median 32 months versus 15 months; P < .0001).","confidence":0.95,"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_4bd9e4c4d47baf8c957322913974bf77"}],"concepts":[{"public_id":"co_09792363983d36eb9a4e54dbe950e795","status":"active","name":"toxicity","description":"The adverse effects associated with a treatment regimen, assessed here for the CVP and R-CVP arms.","types":["safety outcome"],"aliases":[],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_09792363983d36eb9a4e54dbe950e795"},{"public_id":"co_1a5ec83ffa3aced3187ba52b79a48bb2","status":"active","name":"CD20","description":"A B-cell surface antigen that is the molecular target of the rituximab antibody used in this trial.","types":["molecular target"],"aliases":[],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_1a5ec83ffa3aced3187ba52b79a48bb2"},{"public_id":"co_200c37692a7311ad47fb088eb0a498be","status":"active","name":"rituximab","description":"A chimeric monoclonal antibody directed against the CD20 antigen, used in this trial in combination with CVP chemotherapy.","types":["drug","monoclonal antibody"],"aliases":[],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_200c37692a7311ad47fb088eb0a498be"},{"public_id":"co_3bc174906ac68a39dc18dd2a0450920d","status":"active","name":"complete response rate","description":"The proportion of patients achieving complete response to treatment, used as a trial endpoint.","types":["outcome measure"],"aliases":[],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_3bc174906ac68a39dc18dd2a0450920d"},{"public_id":"co_4198797bf818bd133ba1dcb4162033f2","status":"active","name":"overall response rate","description":"The proportion of patients achieving either a complete or partial response to treatment, used as a trial endpoint.","types":["outcome measure"],"aliases":[],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_4198797bf818bd133ba1dcb4162033f2"},{"public_id":"co_49d7c086dc56395a550490a1057cc95a","status":"active","name":"R-CVP","description":"The experimental regimen combining rituximab with the CVP chemotherapy regimen, administered for 8 cycles in this trial.","types":["therapeutic regimen"],"aliases":["CVP plus rituximab"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_49d7c086dc56395a550490a1057cc95a"},{"public_id":"co_7cb1f1a169dbc9d8c3f2db5cc2b72890","status":"active","name":"randomized controlled trial","description":"A study design in which previously untreated patients were randomly assigned to one of two treatment arms for comparison.","types":["study design"],"aliases":["randomly assigned"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_7cb1f1a169dbc9d8c3f2db5cc2b72890"},{"public_id":"co_9d923769074e4f8fc0f8da7ade91c437","status":"active","name":"CVP chemotherapy","description":"A combination chemotherapy regimen of cyclophosphamide, vincristine, and prednisone used as a standard treatment for follicular lymphoma, given here as the control arm.","types":["therapeutic regimen"],"aliases":["CVP","cyclophosphamide, vincristine, and prednisone"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_9d923769074e4f8fc0f8da7ade91c437"},{"public_id":"co_be5cb226c6bac80f20a6d2d299a831a6","status":"active","name":"time to treatment failure","description":"The interval from treatment assignment to treatment failure, used as a trial endpoint.","types":["outcome measure"],"aliases":[],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_be5cb226c6bac80f20a6d2d299a831a6"},{"public_id":"co_bf7c930d0db26b647454ad1fcedaf6a0","status":"active","name":"follicular lymphoma","description":"A type of lymphoma; this trial enrolled previously untreated patients with advanced (stage III to IV) disease.","types":["disease"],"aliases":[],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_bf7c930d0db26b647454ad1fcedaf6a0"},{"public_id":"co_ca597ad4ba35600df728ed5aa29c6168","status":"active","name":"time to progression","description":"The interval from treatment assignment to disease progression, used as a trial endpoint.","types":["outcome measure"],"aliases":[],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_ca597ad4ba35600df728ed5aa29c6168"}],"external_ids":{"DOI":"10.1182/BLOOD-2004-08-3175","ArXiv":null,"PubMed":15494430,"PubMedCentral":null,"MAG":2169578616,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://ashpublications.org/blood/article-pdf/105/4/1417/1706471/zh800405001417.pdf","landing_url":"https://www.semanticscholar.org/paper/2bbd8b1c0d7bd429ead534e9a57c0879b27716d7","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":null,"status":"BRONZE","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":631132,"paper_uid":"e90c27db-17ed-497e-92fe-3104480506cb","canonical_identity":{"paper_id":631132,"paper_uid":"e90c27db-17ed-497e-92fe-3104480506cb","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/22887630"}